CTOs on the Move

Aldeyra Therapeutics, Inc

www.aldeyra.com

 
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.aldeyra.com
  • 15 New England Executive Park
    Burlington, MA USA 01803
  • Phone: 781.270.0630

Executives

Name Title Contact Details

Funding

Aldeyra Therapeutics, Inc raised $60M on 03/26/2019
Aldeyra Therapeutics, Inc raised $74.7M on 01/20/2021
Aldeyra Therapeutics, Inc raised $125M on 04/28/2021

Similar Companies

The Institute for Athletic Medicine

The Institute for Athletic Medicine is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SeraCare Life Sciences

SeraCare Life Sciences, Inc. is a Milford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nucleome Therapeutics

Decoding the dark matter of the human genome to uncover novel ways to treat disease Discover More

Genomenon

Genomenon is an AI-driven genomics company whose mission is to save and improve lives by making genomic information actionable for patients with rare genetic diseases and cancer.

Cullgen

Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches.